Alopecia areata (AA) is an inflammatory cause of unpredictable, patchy hair loss that affects up to 2% of the population. Current treatment options for AA involve local steroid injections at the site of alopecia combined with topical retinoids; however, these are of limited efficacy and are associated with significant adverse effects. Recent insights into the pathogenesis of AA have allowed the development of novel treatment options, in particular, Janus kinase (JAK) inhibitors and cytokine-targeted therapy. There have also been reports of hair regrowth following treatment with platelet-rich plasma, stem cell-based therapy approaches and faecal microbiota transplantation.
Our supporting partners do not constitute an endorsement of the content on this page.
Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
Dr Maria-Angeliki Gkini explores the growing role of psychodermatology in supporting patients’ wider needs, alongside emerging technologies and approaches that could shape the future management of psoriatic disease.
Meet the dermatologists redefining the future of practice, research, and technology Meet the innovators shaping the future of dermatology The touchDERMATOLOGY Future Leaders 2026 have been nominated and selected to recognize the rising stars shaping the future of across the field ...
We are delighted to introduce Dr Olufolakemi Cole-Adeife as a touchDERMATOLOGY Future Leader 2026. Dr Cole-Adeife is a Consultant Physician, Dermatologist and Venereologist at Lagos State University Teaching Hospital (LASUTH) and a Lecturer at Lagos State University College of Medicine in ...
We are delighted to announce Dr Martyna Sławińska as a touchDERMATOLOGY Future Leader 2026. Dr Martyna Sławińska is advancing the field of dermatology through her work on non-invasive skin imaging and its application beyond skin cancer. Based ...
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our LEADderm mini-series exploring non-clinical skills that can help you thrive in your ...
Join us as leading experts discuss key data and perspectives from the late-breaking sessions at this year’s AAD meeting This March, experts from around the world gathered in Denver, Colorado, for the 2026 American Academy of Dermatology (AAD) Annual Meeting. ...
Treatment options for androgenetic alopecia remain limited, fuelling interest in novel therapies that can deliver faster and more meaningful results. In this interview, Prof. Jerry Shapiro explores the challenges of current management and discusses the emerging potential of VDPHL01, an extended-release oral minoxidil formulation that may offer improved efficacy, tolerability and speed of response compared with existing options.
Ultra-high frequency ultrasound is emerging as a valuable tool in the management of alopecia areata (AA). Beyond its established role in visualising hair follicle and scalp structures, it is now being explored for diagnosing AA, distinguishing it from other types of hair loss, and monitoring disease progression across different stages. Crucially, this non-invasive imaging technique also shows promise in predicting and tracking treatment responses, paving the way for more personalised care strategies for patients receiving targeted therapies.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
This year, we are celebrating our inaugural touchDERMATOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform dermatology in the years to come. Representing a diverse range of expertise from across the globe, these highly accomplished clinicians are among the brightest minds shaping the future of dermatology. We had the pleasure of learning about their unique career journeys, motivations, and the inspirations that have guided their paths. They also shared their perspectives on the most exciting developments in dermatology today, along with their hopes for the future of the field. Congratulations to all our touchDERMATOLOGY Future Leaders, and thank you for sharing your stories, insights and ambitions with us.
With a career that bridges continents and disciplines, we are delighted to feature Dr Yi-Kui Xiang in our touchDERMATOLOGY Future Leaders 2025 initiative. Based in Berlin, Germany, Dr Xiang serves as a clinical scientist at both the Charité Institute of Allergology and the Fraunhofer Institute for Immunology and Allergology, but also maintains a clinical role at the Shanghai Skin Disease Hospital in China. His research interests span from urticaria, IgE-mediated autoimmunity and allergology to alopecia, pruritus, psychodermatology and patient-reported outcomes.
Dr Corinne Maiolo is based in Adelaide, where she treats both adult and paediatric patients, with particular interests in acne, rosacea, eczema, psoriasis, and hair loss. She is the founder of myPRODERM and was awarded the La Roche-Posay Research Grant in 2024 for her work in atopic dermatitis. In this Q&A, Dr Corinne Maiolo reflects on the moments that have shaped her career and shares her hopes for the future of dermatological care.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The BRAVE-AA-PEDS study focused on 257 adolescents with severe alopecia areata, investigating the efficacy of baricitinib. The trial demonstrated promising results with 42% achieving significant improvement by week 36, and reassuring safety data.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.